Alpha fetoprotein detection test strip based on directional coupling of nano antibody as well as preparation method and application of alpha fetoprotein detection test strip

Through nano-antibody directed coupling technology, the problem of low detection sensitivity of traditional IgG labeled probes is solved, and the high sensitivity and stability of alpha-fetoprotein detection is achieved, which significantly improves the detection effect.

CN119044500APending Publication Date: 2024-11-29GUANGZHOU MEDICAL UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410945298.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing alpha-fetoprotein detection strips based on traditional IgG labeled probes have low detection sensitivity, poor label stability, and their activity is susceptible to environmental factors.

Method used

Using nano-antibody directed coupling technology, the alpha-fetoprotein nano-antibody and fluorescent microspheres are directedly coupled and modified through the Spytag and Spycatcher system to form a high-active detection marker, and improve the binding site proportion and stability of the detection marker.

Benefits of technology

It significantly improves the sensitivity and specificity of alpha-fetoprotein detection, enhances the biological activity of detection markers, and reduces the sensitivity to environmental factors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119044500A_ABST
    Figure CN119044500A_ABST
Patent Text Reader

Abstract

The invention discloses an alpha fetoprotein detection test strip based on directional coupling of a nano antibody as well as a preparation method and application of the alpha fetoprotein detection test strip. A combination pad of the test strip is coated with a detection marker and a quality control marker; the detection marker comprises a Spytag alpha fetoprotein nano antibody and a SpyCatcher fluorescent microsphere, and the detection marker comprises a Spytag alpha fetoprotein nano antibody and a SpyCatcher fluorescent microsphere; the Spytag alpha fetoprotein nano antibody is formed by fusing a Spytag polypeptide and an alpha fetoprotein nano antibody, and the SpyCatcher fluorescent microsphere is composed of a fluorescent microsphere and a SpyCatcher protein modified on the fluorescent microsphere; the Spytag at alpha fetoprotein nano antibody and the SpyCatcher at fluorescent microspheres are in directional coupling through the Spytag and the SpyCatcher. The alpha fetoprotein nano antibody and the SpyTag polypeptide form the fusion protein, and then the fusion protein and the fluorescent microsphere with the surface modified with the SpyCatcher protein form a covalent bond through Spytag / SpyCatcher specificity, so that the alpha fetoprotein nano antibody is directionally modified on the surface of the fluorescent microsphere, and an alpha fetoprotein recognition site is fully exposed, so that the biological activity of the detection marker can be effectively improved; further, the detection specificity and sensitivity are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical testing technology, and in particular to an alpha-fetoprotein detection test strip based on nano-antibody directional coupling, and a preparation method and application thereof. Background Art

[0002] Alpha-fetoprotein (AFP) is a common tumor marker in liver diseases, especially liver cancer. Abnormally high or low AFP in the serum of pregnant women may indicate abnormal fetal development, such as neural tube defects, abdominal wall defects, etc. Therefore, AFP detection is a biomarker test with broad clinical application value. It can not only help doctors to diagnose and monitor the early treatment of liver cancer, but also be used for pregnancy risk assessment. At present, the detection of AFP mainly relies on enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay. Although these methods have high sensitivity, they are complex to operate, costly and time-consuming.

[0003] Immunochromatography is a rapid detection method based on chromatography and immunolabeling technology, which has the advantages of fast detection speed, low price and simple operation. The labeling probes of existing immunochromatography technology generally modify traditional IgG antibodies on the surface of fluorescent materials by electrostatic adsorption or covalent modification. However, traditional IgG labeling probes have the following disadvantages: 1) large molecular weight (150kD) and small binding site ratio; 2) poor stability, and activity is easily affected by environmental factors (such as pH, salt ions, temperature); 3) random labeling direction, and active sites are easily shielded. These disadvantages will limit the activity of traditional immune markers, thereby inhibiting the sensitivity of test strip detection.

[0004] Therefore, the prior art still needs to be improved and developed. Summary of the invention

[0005] In view of the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide an alpha-fetoprotein test strip based on nano-antibody directional coupling and its preparation method and application, aiming to solve the problem of low detection sensitivity of the existing AFP test strip based on traditional IgG labeled probe.

[0006] The technical solution of the present invention is as follows:

[0007] In a first aspect of the present invention, there is provided an alpha-fetoprotein detection test strip based on nano-antibody directional coupling, comprising a base plate and a sample pad, a conjugate pad, a nitrocellulose membrane and a blotting paper sequentially overlapped on the base plate;

[0008] Wherein, the binding pad is coated with detection markers and quality control markers; the detection markers include Spytag@AFP nanoantibody and SpyCatcher@fluorescent microspheres; the Spytag@AFP nanoantibody is composed of a fusion of Spytag polypeptide and AFP nanoantibody, and the SpyCatcher@fluorescent microspheres are composed of fluorescent microspheres and SpyCatcher proteins modified on the fluorescent microspheres; the Spytag@AFP nanoantibody and the SpyCatcher@fluorescent microspheres are directionally coupled via Spytag and Spycatcher;

[0009] The nitrocellulose membrane is provided with a detection line and a quality control line in sequence along the chromatography direction; the detection line is coated with IgG antibody of alpha-fetoprotein, and the quality control line is coated with quality control antibody; the quality control marker and the quality control antibody can specifically bind.

[0010] In a preferred technical solution, the amino acid sequence of the alpha-fetoprotein nanobody is as shown in SEQ ID NO.1.

[0011] A preferred technical solution is that in the Spytag@AFP nanobody, the Spytag polypeptide and the AFP nanobody are connected by an amino acid flexible bridge.

[0012] According to a preferred technical solution, in the conjugate pad, the content of the detection marker is 0.05-1 μg, and the content of the quality control marker is 0.005-0.2 μg.

[0013] According to a preferred technical solution, on the detection line, the coating amount of the IgG antibody against alpha-fetoprotein is 0.5-2 μL / cm, and the concentration is 0.5-2 mg / mL.

[0014] According to a preferred technical solution, on the quality control line, the coating amount of the quality control antibody is 0.5-2 μL / cm, and the concentration is 0.1-0.5 mg / mL.

[0015] In a preferred technical solution, the quality control marker is fluorescent microspheres labeled with IgG, wherein the IgG is selected from one of rabbit IgG, chicken IgG, and mouse IgG.

[0016] In a preferred technical solution, the quality control antibody is selected from one of goat anti-rabbit IgG, rabbit anti-chicken IgG or goat anti-mouse IgG.

[0017] The second aspect of the present invention provides a method for preparing the alpha-fetoprotein test strip as described in the first aspect, comprising:

[0018] The detection marker and the quality control marker are coated on the conjugate pad and stored in a dry state;

[0019] The IgG antibody of alpha-fetoprotein is coated on the detection line of the nitrocellulose membrane, and the quality control antibody is coated on the quality control line, and then the membrane is dried and stored;

[0020] Add sample buffer to the sample pad and store it dry;

[0021] The sample pad, conjugate pad, nitrocellulose membrane and absorbent paper are overlapped on the bottom plate in sequence, and assembled with the card shell after cutting to form a test paper strip.

[0022] The third aspect of the present invention provides a use of the alpha-fetoprotein test strip as described in the first aspect in the preparation of a liver cancer diagnosis product.

[0023] Beneficial effects: The present invention uses alpha-fetoprotein nanoantibodies as recognition elements, and realizes directional coupling of alpha-fetoprotein nanoantibodies through the mediation of the Spytag / Spycatcher system, providing an important means for the preparation of highly active detection markers. Compared with traditional IgG antibodies, alpha-fetoprotein nanoantibodies have a large proportion of binding sites and high stability, and can be fused with Spytag polypeptides through seamless cloning technology, and directionally coupled with fluorescent microspheres modified with Spycatchers through Spytag / Spycatcher reactions, thereby achieving efficient directional modification of alpha-fetoprotein nanoantibodies and retaining the biological activity of alpha-fetoprotein nanoantibodies to the greatest extent. In addition, the alpha-fetoprotein nanoantibody of the present invention has a small molecular weight, and compared with traditional IgG antibodies, a single fluorescent microsphere contains more recognition sites, which can effectively improve the affinity of the detection marker for alpha-fetoprotein, thereby improving the detection sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Schematic diagram of the test strip structure of Example 1.

[0025] Figure 2 This is the standard curve of the AFP calibrant detected by the test strip prepared using red AIE fluorescent microspheres in Example 1.

[0026] Figure 3 This is the standard curve of the AFP calibrant detected by the test strip prepared using the green AIE fluorescent microspheres in Example 1.

[0027] Figure 4 This is a graph showing the results of the test strip of Example 1 detecting an AFP standard.

[0028] Figure 5 It is a comparison chart of the detection results of real clinical samples in Example 1 and chemiluminescence. DETAILED DESCRIPTION

[0029] The present invention provides an alpha-fetoprotein detection test strip based on nano-antibody directional coupling and a preparation method and application thereof. In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail below.

[0030] The embodiment of the present invention provides an alpha-fetoprotein detection test strip based on nano-antibody directional coupling, comprising a base plate and a sample pad, a conjugate pad, a nitrocellulose membrane and a blotting paper sequentially overlapped on the base plate;

[0031] Wherein, the binding pad is coated with detection markers and quality control markers; the detection markers include Spytag@AFP nanoantibody and SpyCatcher@fluorescent microspheres; the Spytag@AFP nanoantibody is composed of a fusion of Spytag polypeptide and AFP nanoantibody, and the SpyCatcher@fluorescent microspheres are composed of fluorescent microspheres and SpyCatcher proteins modified on the fluorescent microspheres; the Spytag@AFP nanoantibody and the SpyCatcher@fluorescent microspheres are directionally coupled via Spytag and Spycatcher;

[0032] The nitrocellulose membrane is provided with a detection line and a quality control line in sequence along the chromatography direction; the detection line is coated with IgG antibody of alpha-fetoprotein, and the quality control line is coated with quality control antibody; the quality control marker and the quality control antibody can specifically bind.

[0033] The present invention forms a fusion protein by combining an alpha-fetoprotein nanobody with a SpyTag polypeptide, and then forms a covalent bond with a fluorescent microsphere whose surface is modified with a SpyCatcher protein through Spytag / Spycatcher specificity, so that the alpha-fetoprotein nanobody is directionally modified on the surface of the fluorescent microsphere, fully exposing the alpha-fetoprotein recognition site, thereby effectively improving the biological activity of the detection marker, and further improving the specificity and sensitivity of the detection.

[0034] In one embodiment, the amino acid sequence of the alpha-fetoprotein nanobody is as shown in SEQ ID NO.1.

[0035] SEQ ID NO.1:

[0036] QVQLVESGGGLVQSGGSLRLSCAASMRGFRIVAGGWYRQSPGKQRELVA DINYQDDTNYGDFVKGRFTISRDSAKNTLYLQMNSLKPEDTAVYYCSALSVI GNEFWGQGTQVTVSSEPKTPKPQ.

[0037] In one embodiment, the amino acid sequence of the Spytag polypeptide is shown as SEQ ID NO.2.

[0038] SEQ ID NO.2:

[0039] RGVPHIVMVDAYKRYK.

[0040] In one embodiment, the amino acid sequence of the SpyCatcher protein is shown in SEQ ID NO.3.

[0041] SEQ ID NO.3:

[0042] VTTLSGLSGEQGPSGDMTTEEDSATHIKFSKRDEDGRELAGATMELRDSS GKTISTWISDGHVKDFYLYPGKYTFVETAAPDGYEVATPIEFTVNEDGQVTVD GEATEGDAHT.

[0043] In one embodiment, in the Spytag@AFP nanobody, the Spytag polypeptide and the AFP nanobody are connected by an amino acid flexible bridge.

[0044] In one embodiment, the Spytag@AFP nanobody is prepared by seamless cloning technology. Specifically, the gene of the AFP nanobody (NAb) is fused with the gene of the Spytag polypeptide by seamless cloning technology, and then expressed to obtain a fusion protein (NAb-Spytag).

[0045] In one embodiment, in the conjugate pad, the content of the detection marker is 0.05-1 μg, and the content of the quality control marker is 0.005-0.2 μg.

[0046] In one embodiment, on the test line, the coating amount of the IgG antibody against alpha-fetoprotein is 0.5-2 μL / cm, and the concentration is 0.5-2 mg / mL.

[0047] In one embodiment, on the quality control line, the coating amount of the quality control antibody is 0.5-2 μL / cm, and the concentration is 0.1-0.5 mg / mL.

[0048] In one embodiment, the quality control marker is fluorescent microspheres labeled with IgG, wherein the IgG is selected from one of rabbit IgG, chicken IgG, and mouse IgG.

[0049] In one embodiment, the quality control antibody is selected from one of goat anti-rabbit IgG, rabbit anti-chicken IgG or goat anti-mouse IgG.

[0050] In one embodiment, in the SpyCatcher@ fluorescent microspheres, the mass ratio of the SpyCatcher protein to the fluorescent microspheres is (0.08-0.16):1.

[0051] In one embodiment, in the detection marker, the coupling mass ratio of the Spytag@ alpha-fetoprotein nanoantibody and the SpyCatcher@ fluorescent microspheres is (0.06-0.12):1.

[0052] In one embodiment, the preparation method of the SpyCatcher@ fluorescent microspheres comprises the following specific steps: washing the fluorescent microspheres 2-3 times with ultrapure water, diluting the fluorescent microspheres with a labeling buffer, then adding Spycatcher protein, and then adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) three times, mixing, reacting at room temperature for 30-60 minutes, adding a blocking agent after the reaction, reacting at room temperature for 1-2 hours, centrifuging to remove the supernatant, re-dissolving the precipitate with a probe preservation solution, and storing it in a 4°C refrigerator for later use. The Spycatcher protein is modified on the surface of the fluorescent microspheres by a covalent modification method.

[0053] Among them, preferably, the labeling buffer is selected from 0.005-0.05M phosphate (PB) buffer (pH=5.5-7.4) or 0.01-0.05M 2-(N-morpholino)ethanesulfonic acid (MES) solution (pH=5-8); the mass ratio of the Spycatcher protein to the fluorescent microspheres is (0.04-0.16):1, and the mass ratio of the EDC to the fluorescent microspheres is (0.005-0.02):1; the fluorescent microspheres are selected from aggregation-induced emission (AIE) fluorescent microspheres; the probe preservation solution is a 0.01M phosphoric acid (PB) solution with a pH of 7-8 containing 5-25% sucrose (M:V), 10-20% trehalose (M:V), and 0.01-1% sodium azide (M:V).

[0054] The embodiment of the present invention provides a method for preparing the alpha-fetoprotein test strip as described above, comprising:

[0055] The detection marker and the quality control marker are coated on the conjugate pad and stored in a dry state;

[0056] The IgG antibody of alpha-fetoprotein is coated on the detection line of the nitrocellulose membrane, and the quality control antibody is coated on the quality control line, and then the membrane is dried and stored;

[0057] Add sample buffer to the sample pad and store it dry;

[0058] The sample pad, conjugate pad, nitrocellulose membrane and absorbent paper are overlapped on the bottom plate in sequence, and assembled with the card shell after cutting to form a test paper strip.

[0059] An embodiment of the present invention provides a use of the alpha-fetoprotein test strip as described above in the preparation of a liver cancer diagnosis product.

[0060] The present invention will be further described below by means of specific examples.

[0061] Example 1

[0062] This embodiment provides an alpha-fetoprotein detection test strip based on nano-antibody directional coupling, as follows:

[0063] 1. Preparation of Spytag@α-fetoprotein nanoantibody fusion protein (NAb-Spytag):

[0064] (1) According to the seamless cloning technology, the genes of Spytag and AFP nanobody (NAb) were recombined to prepare a plasmid carrying the target gene (ordered from Suzhou Jinweizhi Biotechnology Co., Ltd.). The nucleotide sequence after fusion is shown in SEQ ID NO.4, and the amino acid sequence after fusion is shown in SEQ ID NO.5.

[0065] SEQ ID NO.4:

[0066] .

[0067] SEQ ID NO.5:

[0068] QVQLVESGGGLVQSGGSLRLSCAASMRGFRIVAGGWYRQSPGKQRELVADINYQDDTNYGDFVKGRFTISRDSAKNTLYLQMNSLKPEDTAVYYCSALSVIGNEFWGQGTQVTVSSEPKTPKPQAAALEGGGGSRGVPHIVMVDAYKRYKLEIKRASQPELAPEDPEDVEHHHHHH.

[0069] (2) According to the kit operating procedures, the plasmid carrying the target gene was introduced into the competent cells of the Escherichia coli BL21 strain, the recombinant protein was expressed by the autoinduction method, and the protein was purified using a nickel protein purification column. The protein was stored in 0.01 M PBS buffer at pH = 7.4, and the protein concentration (2 mg / mL) was measured.

[0070] 2. Preparation of SpyCatcher@ fluorescent microspheres:

[0071] (1) The preparation of SpyCatcher protein is the same as step 1.

[0072] (2) Preparation of detection markers:

[0073] A. Take 1 mL of 2-ethanesulfonic acid (MES) buffer (pH = 6.0), 50 μL of 1% w / v red or green AIE fluorescent microsphere solution, 2 μL of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) solution (20 mg / mL) and 2 μL of N-hydroxysulfosuccinimide (sulfo-NHS) solution (55 mg / mL) and mix them evenly. After shaking at 300 rpm at room temperature for 15 minutes, 1.4 μL of 2-mercaptoethanol was added to inactivate EDC, and the mixture was centrifuged (5000 rpm) for 5 minutes. The solid product was collected and washed twice with 200 μL of 2-(N-morpholino)ethanesulfonic acid (MES) buffer.

[0074] B. The purified solid product was dispersed in 600 μL 1×PBS buffer (pH=7.4) to prepare an activated fluorescent nanoparticle solution. Take 200 μL of activated fluorescent nanoparticle solution and 200 μL SpyCatcher (0.25 mg / mL) and add them to a 1.5 mL tube. After shaking at 150 rpm for 1 hour at room temperature, add 100 μL of 1×PBS buffer containing 1% bovine serum albumin (BSA) and react based on shaking for 1 hour. Subsequently, the mixture was centrifuged at 6000 rpm for 4 min at 0-4°C to collect the solid product. The solid product was dispersed in 1 mL μL phosphoric acid (pH=7.4) buffer solution.

[0075] 3. Preparation of detection markers:

[0076] Add 20 μL of NAb-Spytag protein solution to the above SpyCatcher@ fluorescent microspheres, shake for 30 min, centrifuge for 5 min (4°C, 6000 rpm), and redissolve the precipitate in 200 μL of 0.01 M Tris hydrochloric acid buffer (containing 5% sucrose, 10% trehalose, and 0.02% sodium azide).

[0077] 4. Preparation of quality control line markers:

[0078] The method is the same as step 3, except that the SpyCatcher@ fluorescent microspheres are replaced with rabbit IgG of equal mass concentration.

[0079] 5. Preparation of conjugate pad:

[0080] Dilute the detection marker and quality control marker with a diluent containing 0.1 M sodium chloride, 20 mM ethylenediaminetetraacetic acid, 1% (w / v) BSA, 1% (w / v) sucrose and 0.02% (w / v) sodium azide to prepare a mixed solution of the detection marker and quality control marker with a final concentration of 50 μg / mL and 5 μg / mL, respectively. Spray it on the conjugate pad at a spray volume of 2 μL / cm, dry it at 37°C for 3 hours, and store it dry and sealed.

[0081] 6. Preparation of test line and quality control line on nitrocellulose membrane:

[0082] 1 mg / mL AFP antibody (a-Fetapmtein (AFP), Human, #5H7, Shenzhen Yazheng Biotechnology Co., Ltd.) and 0.5 mg / mL goat anti-rabbit IgG were sprayed on the nitrocellulose membrane at a spray volume of 1 μL / cm as the test line and quality control line. The distance between the test line and the quality control line was 5 mm. Dry at 37°C for 1 hour.

[0083] 7. Preparation of sample pad:

[0084] The sample pad is made of glass fiber. The 15×300 mm sample pad is saturated with 30 mM sodium phosphate buffer at pH=8.0, which contains 0.5% (w / v) bovine serum albumin, 0.5% (w / v) PVP, 0.5% (w / v) sucrose, 0.1% (w / v) Triton-X, 0.1% (w / v) sheep IgG, 0.1% (w / v) blocking agent HBR, 0.02% ethylenediaminetetraacetic acid (EDTA) and 0.01% (w / v) sodium azide, and then dried for storage.

[0085] 8. Assembly of test strips

[0086] The sample pad, marking pad, coating film and absorbent paper are sequentially adhered to the PVC base plate in an overlapping manner to obtain a large test paper plate, which is cut into 3.9 mm wide test paper strips according to the cutting requirements, and assembled into test paper cards, which are placed in a dry environment for use.

[0087] The structural diagram of the test strip is as follows Figure 1 As shown in the figure, ① sample pad; ② binding pad; ③ nitrocellulose membrane; ④ detection line; ⑤ control line; ⑥ absorbent paper; ⑦ PVC bottom plate; ⑧ detection marker and quality control marker; ⑨ IgG antibody of alpha-fetoprotein; ⑩ quality control antibody.

[0088] 9. Preparation of AFP Calibrators:

[0089] (1) Weigh 4 g BSA and 40 μL preservative (Procolin 300), calibrate to 40 mL with sodium phosphate buffer (0.01 MPBS, pH = 8.0), and place at 2-8°C for use.

[0090] (2) The commercially available recombinant human AFP protein was prepared into calibrants of different concentration gradients using a calibrant diluent, and calibrated using a commercial kit approved by the State Food and Drug Administration. Each concentration gradient was tested three times, and the average value of the test results was taken. The values ​​were set as 0 pg / mL (calibrant diluent, no AFP protein added), 0.1 ng / mL, 0.5 ng / mL, 1 ng / mL, 5 ng / mL, and 10 ng / mL, respectively. Each standard was prepared into 110 μL, placed in a suitable container, and labeled to make a semi-finished product.

[0091] 10. Test strip test:

[0092] The AFP calibrator solution in step 9 was tested with the prepared test paper card. Each concentration was tested three times. The signal ratio (T / C) of the corresponding detection line fluorescence signal and the quality control line C line was recorded as the ordinate, and a standard curve was drawn, as shown in Table 1 and Figure 2-4 shown.

[0093] Table 1: Performance analysis of AFP detection kit (standard product test)

[0094] Fluorescent microspheres 0 0.1 0.5 1 5 10 T / C AFP Red 0.029434 0.093057 0.313375 0.610114 2.60953 4.740577 T / C AFP Green 0.053107 0.128061 0.438503 0.782063 4.029456 6.889381

[0095] 11. Clinical sample testing:

[0096] 50 serum samples from liver cancer patients were collected, and the serum samples were simultaneously detected using the test strips of the embodiment of the present invention and the reference kit (Roche electrochemiluminescence method). 70 μL of the serum sample was added to the sample well, and the T / C ratio was measured after chromatography for 10 minutes. The detection concentration was recorded according to the standard curve and compared with the chemiluminescence method. Figure 5 shown.

[0097] In summary, the present invention provides an alpha-fetoprotein detection test strip based on directional coupling of nano antibodies, comprising a bottom plate and a sample pad, a conjugation pad, a nitrocellulose membrane and absorbent paper overlapped in sequence on the bottom plate; wherein the conjugation pad is coated with a detection marker and a quality control marker; the detection marker comprises Spytag@alpha-fetoprotein nanoantibody and SpyCatcher@fluorescent microspheres; the Spytag@alpha-fetoprotein nanoantibody is composed of a fusion of Spytag polypeptide and alpha-fetoprotein nanoantibody, and the SpyCatcher@fluorescent microspheres are composed of fluorescent microspheres and SpyCatcher proteins modified on the fluorescent microspheres; the Spytag@alpha-fetoprotein nanoantibody and the SpyCatcher@fluorescent microspheres are directionally coupled through Spytag and Spycatcher; a detection line and a quality control line are sequentially arranged on the nitrocellulose membrane along the chromatography direction, the detection line is coated with an IgG antibody of alpha-fetoprotein, and the quality control line is coated with a quality control antibody; the quality control marker and the quality control antibody can specifically bind.

[0098] The present invention uses alpha-fetoprotein nanoantibodies as recognition elements, and realizes directional coupling of alpha-fetoprotein nanoantibodies through the mediation of the Spytag / Spycatcher system, providing an important means for the preparation of highly active detection markers. Compared with traditional IgG antibodies, alpha-fetoprotein nanoantibodies have a large proportion of binding sites and high stability, and can be fused with Spytag polypeptides through seamless cloning technology, and directional coupling with fluorescent microspheres modified with Spycatchers through Spytag / Spycatcher reactions, thereby realizing efficient directional modification of alpha-fetoprotein nanoantibodies and retaining the biological activity of alpha-fetoprotein nanoantibodies to the greatest extent. In addition, the alpha-fetoprotein nanoantibody of the present invention has a small molecular weight, and compared with traditional IgG antibodies, a single fluorescent microsphere contains more recognition sites, which can effectively improve the affinity of the detection marker to alpha-fetoprotein, thereby improving the detection sensitivity.

[0099] It should be understood that the application of the present invention is not limited to the above examples. For ordinary technicians in this field, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.

Claims

1. An alpha-fetoprotein test strip based on directional coupling of nano-antibodies, comprising a base plate and a sample pad, a conjugate pad, a nitrocellulose membrane and a blotting paper sequentially overlapped on the base plate; characterized in that: The binding pad is coated with detection markers and quality control markers; the detection markers include Spytag@AFP nanoantibody and SpyCatcher@fluorescent microspheres; the Spytag@AFP nanoantibody is composed of a fusion of Spytag polypeptide and AFP nanoantibody, and the SpyCatcher@fluorescent microspheres are composed of fluorescent microspheres and SpyCatcher proteins modified on the fluorescent microspheres; the Spytag@AFP nanoantibody and the SpyCatcher@fluorescent microspheres are directionally coupled via Spytag and Spycatcher; The nitrocellulose membrane is provided with a detection line and a quality control line in sequence along the chromatography direction; the detection line is coated with IgG antibody of alpha-fetoprotein, and the quality control line is coated with quality control antibody; the quality control marker and the quality control antibody can specifically bind.

2. The alpha-fetoprotein test strip according to claim 1, characterized in that: The amino acid sequence of the alpha-fetoprotein nanobody is shown in SEQ ID NO.

1.

3. The alpha-fetoprotein test strip according to claim 1, characterized in that: In the Spytag@AFP nanobody, the Spytag polypeptide and the AFP nanobody are connected via an amino acid flexible bridge.

4. The alpha-fetoprotein test strip according to claim 1, characterized in that: In the conjugate pad, the content of the detection marker is 0.05-1 μg, and the content of the quality control marker is 0.005-0.2 μg.

5. The alpha-fetoprotein test strip according to claim 1, characterized in that: On the test line, the coating amount of the IgG antibody of alpha-fetoprotein is 0.5-2 μL / cm, and the concentration is 0.5-2 mg / mL.

6. The alpha-fetoprotein test strip according to claim 1, characterized in that: On the quality control line, the coating amount of the quality control antibody is 0.5-2 μL / cm, and the concentration is 0.1-0.5 mg / mL.

7. The alpha-fetoprotein test strip according to claim 1, characterized in that: The quality control marker is a fluorescent microsphere labeled with IgG, wherein the IgG is selected from one of rabbit IgG, chicken IgG and mouse IgG.

8. The alpha-fetoprotein test strip according to claim 7, characterized in that: The quality control antibody is selected from one of goat anti-rabbit IgG, rabbit anti-chicken IgG or goat anti-mouse IgG.

9. A method for preparing an alpha-fetoprotein test strip according to any one of claims 1 to 8, characterized in that: include: The detection marker and the quality control marker are coated on the conjugate pad and stored in a dry state; The IgG antibody of alpha-fetoprotein is coated on the detection line of the nitrocellulose membrane, and the quality control antibody is coated on the quality control line, and then the membrane is dried and stored; Add sample buffer to the sample pad and store it dry; The sample pad, conjugate pad, nitrocellulose membrane and absorbent paper are overlapped on the bottom plate in sequence, and assembled with the card shell after cutting to form a test paper strip.

10. Use of the alpha-fetoprotein test strip according to any one of claims 1 to 8 in preparing a liver cancer diagnosis product.